Artificial Intelligence, or AI, is now transforming how we detect, prevent and treat illness, promising earlier interventions, smarter therapies and more affordable care for everyone.​ ...

In the MIROCALS trial, Gilbert Bensimon and colleagues1 showed that low-dose interleukin-2 (IL-2) added to riluzole did not significantly reduce mortality in an unadjusted analysis of patients with ...

We thank Yutaka Shimazu for his insightful comments. We agree that our positive findings1–4 highlight the urgent need for further work on biomarkers of neuronal damage and immune mechanisms in ...

MapQuest founder and other national figures join local and regional leaders Thursday and Friday for Roanoke Blacksburg Technology Council-hosted event at Hotel Roanoke.

Nigel Langley of gChem discusses the company’s DMSO, proactive pharma strategies, and more in part 1 of a 2-part interview ...